Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.

MLA

Piras-Douce, Fabienne, et al. “Next Generation Live-Attenuated Yellow Fever Vaccine Candidate: Safety and Immuno-Efficacy in Small Animal Models.” Vaccine, vol. 39, no. 13, Mar. 2021, pp. 1846–56. EBSCOhost, https://doi.org/10.1016/j.vaccine.2021.02.033.

APA

Piras-Douce, F., Raynal, F., Raquin, A., Girerd-Chambaz, Y., Gautheron, S., Sanchez, M. E. N., Vangelisti, M., & Mantel, N. (2021). Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models. Vaccine, 39(13), 1846–1856. https://doi.org/10.1016/j.vaccine.2021.02.033

Chicago

Piras-Douce, Fabienne, Franck Raynal, Alix Raquin, Yves Girerd-Chambaz, Sylviane Gautheron, Martha Erika Navarro Sanchez, Manuel Vangelisti, and Nathalie Mantel. 2021. “Next Generation Live-Attenuated Yellow Fever Vaccine Candidate: Safety and Immuno-Efficacy in Small Animal Models.” Vaccine 39 (13): 1846–56. doi:10.1016/j.vaccine.2021.02.033.